Since 2010, many new agents have joined our armamentarium for treating metastatic CRPC, raising the question of how best to sequence them. For men with newly diagnosed, presumably hormone-sensitive mPC, we usually start treatment with either abiraterone acetate or docetaxel. Therefore, although we have five or six approved treatments for mCRPC, not every patient should receive all of them.
Click here to read more…….
While not appropriate for every prostate cancer patient, genomic testing can provide a man and his care team with valuable information at various stages of disease management specific to whether the cancer is likely to be aggressive or indolent, thereby helping him to make an informed decision on how to best address his prostate cancer.
Read more about Genetics vs. Genomics, Tools and Tests available here
The American Urological Association (AUA) has just issued a complete set of new guidelines by Mulhall et al. entitled “Evaluation and management of testosterone deficiency: AUA guideline” which includes specific guidance about the appropriateness of testosterone supplements in men diagnosed with prostate cancer.
Read the article on The Prostate Cancer Infolink here
Read the PCRI Spring 2018 Prostate Digest here
In this blog here, PCRI presents an article from guest contributor, J. Curtis Nickel, MD, FRCSC.
As you know, Cancer CAREpoint provides free non-medical support to cancer patients, survivors and their families and caregivers. As more and more people become survivors we are expanding our programs to help them transition to their new post-cancer lives. Many cancer survivors share the struggle to develop their “new normal.” The goal is to acknowledge the trauma that is cancer diagnosis and treatment, but not to allow that diagnosis to take over the rest of your life. If you are done with active treatment, please consider the following programs:
- Cancer Survivorship 101: A two hour survivorship seminar in Fremont at PAMF on 4/21 at 10:00 am
- Survivorship Workshop Series: 6 week series for people who are interested in processing the emotional impact of cancer treatment. Learn about practical tools and resources to help move forward after cancer. Next series starts on Wednesday, May 2 at 6:00 pm at our Resource Center. Please call for other dates.
- Eating for Health– Survivor Nutrition: A four week nutrition series led by Nancy Birang, BS, MT (ASCP), NC starting on June 20 at 6:30 pm at our Resource Center.
Here is the calendar for May. We also have a new nutrition program that I am very excited about! Cancer CAREpoint purchased a set of videos narrated by Rebecca Katz, the famous author of the Cancer Fighting Kitchen cookbook. The programs are interesting, colorful and easy to understand. We will watch about 45 minutes of the program on each of two nights and our nutritionist Stephanie Figueroa, NC, will be there to answer questions and provide samples of the food prepared on the show. This nutrition class will meet on Monday, May 14th and May 21st at 6:30 at our Resource Center, please plan to attend both nights.
Thanks for your interest and support, as always, feel free to call or email if you have questions or concerns.
Sheryl Brown – Director of Operations and Programs
Cancer CAREpoint, 2505 Samaritan Dr., Suite 402
San Jose, CA 95124
The February 2018 Prostatepedia publication focuses on helping patients cope with the emotional impact of a prostate cancer diagnosis and its treatment.
Read the February 2018 Prostatepedia HERE
Check out the UsTOO Page on Anxiety and Depression HERE
National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Read more on curetuday.com HERE
February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This clinical setting is when men who are being treated with Androgen deprivation therapy (ADT) see their PSA levels begin to rise, but no metastases are visible yet on scans. There were previously no FDA-approved treatments for non-metastatic CRPC, and patients typically continued to receive ADT, despite its diminishing benefit.
To read more about this, click HERE.
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on